HC Wainwright Issues Positive Forecast for Scholar Rock (NASDAQ:SRRK) Stock Price

Scholar Rock (NASDAQ:SRRK) had its price target lifted by HC Wainwright from $40.00 to $50.00 in a research report released on Tuesday, Marketbeat.com reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Scholar Rock’s FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

Several other equities research analysts have also commented on the company. BMO Capital Markets upped their price objective on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, October 11th. Piper Sandler lifted their price objective on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Wedbush increased their target price on shares of Scholar Rock from $40.00 to $47.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. Truist Financial lifted their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, October 14th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average price target of $40.43.

Scholar Rock Stock Performance

SRRK stock opened at $39.90 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock has a 1 year low of $6.76 and a 1 year high of $43.38. The company has a market cap of $3.74 billion, a P/E ratio of -16.23 and a beta of 0.47. The stock’s fifty day moving average price is $24.88 and its 200-day moving average price is $14.70.

Insider Buying and Selling at Scholar Rock

In related news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the completion of the transaction, the insider now directly owns 10,850,005 shares of the company’s stock, valued at approximately $417,616,692.45. This represents a 3.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Edward H. Myles sold 206,240 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $26.56, for a total value of $5,477,734.40. Following the transaction, the chief financial officer now owns 161,088 shares of the company’s stock, valued at $4,278,497.28. This represents a 56.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,823,322 shares of company stock worth $56,411,627. Insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SRRK. Mirae Asset Global Investments Co. Ltd. increased its position in Scholar Rock by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock worth $25,000 after purchasing an additional 514 shares during the last quarter. Quarry LP grew its stake in shares of Scholar Rock by 3,443.3% in the 3rd quarter. Quarry LP now owns 4,500 shares of the company’s stock worth $36,000 after buying an additional 4,373 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of Scholar Rock in the 2nd quarter worth about $98,000. Hsbc Holdings PLC purchased a new stake in shares of Scholar Rock during the 2nd quarter valued at about $100,000. Finally, Point72 DIFC Ltd bought a new position in shares of Scholar Rock in the 2nd quarter valued at about $103,000. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.